ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

New Option For Chronic Fatigue Syndrome

The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol

Stop Bacteria With Nature's Antibiotics

Vitamin D Deficiency Linked to Neurological Diseases; Also Raises Risk of Asthma Attacks, and More

New Test Shows Promise in Identifying New Drugs to Treat Lyme Disease

Coenzyme Q10 Helps Veterans Battle Gulf War Illness Symptoms

Strengthen Cell Function with Energy-Boosting Niagen

Dietary Flavanols Reverse Age-Related Memory Decline

Vitamin D deficiency increases poor brain function after cardiac arrest by sevenfold

Study: Doubling saturated fat in the diet does not increase saturated fat in blood

 
Print Page
Email Article

Savella Effective for Long-Term Treatment of Fibromyalgia

  [ Not Yet Rated ]   [ Discuss This Article ]
www.ProHealth.com • October 7, 2013


Note: You may download the full text of this article free HERE.

Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.

By Daniel J Clauw, et al.

Abstract:

INTRODUCTION: Previous studies of long-term treatment response in fibromyalgia and other chronic pain states have generally been limited to approximately a year, leaving questions about the longer-term durability of response. The purpose of this study was to demonstrate continuing efficacy of milnacipran by characterizing changes in pain and other fibromyalgia symptoms after discontinuing long-term treatment. The mean length of milnacipran treatment at time of randomized withdrawal was 36.1 months from initial exposure to milnacipran (range, 17.9 to 54.4 months).

METHODS:
After completing a long-term, open-label, lead-in study of milnacipran (which followed varying periods of exposure in previous studies), adult patients with fibromyalgia entered the 4-week open-label period of the current study for evaluation of ongoing treatment response. After the 4-week period to confirm new baseline status, 151 patients taking milnacipran [greater than or equal to]100 mg/day and reporting [greater than or equal to]50% improvement from pre-milnacipran exposure in visual analog scale (VAS) pain scores were classified as responders.

These responders entered the 12-week, double-blind, withdrawal period in which they were randomized 2:1 to continue milnacipran or switch to placebo. The prespecified primary parameter was loss of therapeutic response (LTR), defined as increase in VAS pain score to <30% reduction from pre-milnacipran exposure, or worsening of fibromyalgia requiring alternative treatment. Adverse events and vital signs were also monitored.

RESULTS:

  • Time to LTR was shorter in patients randomized to placebo than in patients continuing milnacipran (P<0.001).

  • Median time to LTR was 56 days with placebo and not calculable for milnacipran since less than half of these patients lost therapeutic response by study end.

  • Additionally, 81% of patients continuing on milnacipran maintained clinically meaningful pain response ([greater than or equal to]30% improvement from pre-milnacipran exposure), compared with 58% of patients switched to placebo (sensitivity analysis II; P<0.001).

  • Incidence of treatment-emergent adverse events was 58% and 47% for placebo and milnacipran, respectively.

  • Mean decreases in blood pressure and heart rate were found in both groups, with greater decreases for patients switched to placebo.

CONCLUSIONS: Continuing efficacy of milnacipran was demonstrated by the loss of effect following withdrawal of treatment in patients who received an average of 3 years of milnacipran treatment.

Source: Arthritis Research & Therapy, August 16, 2013. By Daniel J Clauw, Philip J Mease, Robert H Palmer, Joel M Trugman and Yong Wang.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Black Friday Sale

Featured Products

Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
VIDEO: Healthy Eating and Fibromyalgia VIDEO: Healthy Eating and Fibromyalgia
A Breakthrough for Mitochondrial Dysfunction A Breakthrough for Mitochondrial Dysfunction
Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance
Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing